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Mature Results from a Phase II Trial of Postoperative
Concurrent Chemoradiotherapy for Poor Prognosis Cancer
of the Esophagus and Gastroesophageal Junction
David J. Adelstein, MD,* Thomas W. Rice, MD,† Lisa A. Rybicki, MS,‡ Jerrold P. Saxton, MD,§
Gregory M. M. Videtic, MD,§ Sudish C. Murthy, MD,† David P. Mason, MD,†
Cristina P. Rodriguez, MD,* and Denise I. Ives, RN*
Introduction: Mature results are presented from a phase II trial of
postoperative concurrent chemoradiotherapy in patients with poor-
prognosis cancer of the esophagus and gastroesophageal junction
after primary surgical resection.
Methods: Resected patients with a pathologic stage of T3, N1, or
M1a were eligible for this trial. Concurrent chemoradiotherapy was
begun between 6 and 10 weeks after surgery and consisted of
radiotherapy (1.8 Gy/d to a planned dose of 50.4–59.4 Gy), con-
current with two cycles of 5-fluorouracil (1000 mg/m2/d) and
cisplatin (20 mg/m2/d), both given as 4-day continuous intravenous
infusions during the first and fourth weeks of the radiation.
Results: Between 1995 and 2006, 50 patients were enrolled. The
median age was 59 (range, 33–76) years, and most patients were
male (86%), Caucasian (96%), and had undergone a transthoracic
esophagogastrectomy (74%) for what proved to be a node positive
(86%) adenocarcinoma (86%). Postoperative concurrent chemora-
diotherapy was accompanied by neutropenia requiring hospitaliza-
tion for fever in only four patients (8%) and no toxic deaths. With
a median follow-up of 47 (range, 36–124) months, the Kaplan-
Meier 4-year projected overall survival is 51%, freedom from
recurrence 50%, distant metastatic control 56%, and locoregional
control 86%. An earlier pathologic stage was the only predictor for
a better outcome.
Conclusions: This schedule of postoperative concurrent chemora-
diotherapy has acceptable toxicity for patients with poor-prognosis
esophageal and gastroesophageal junction cancer after surgery. Out-
comes are better than historical results after surgery alone and justify
further investigation of this approach.
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Despite recent advances in our understanding and treat-ment, esophageal cancer continues to have a very poor
overall prognosis.1,2 Patients with this malignancy typically
present late in their disease course, often with locoregionally
advanced or distant metastatic involvement. As for most solid
tumors, the single most important prognostic factor for sur-
vival has been the pathologic disease stage at diagnosis.
Patients presenting with early carcinoma in situ or with T1
primary legions, with no nodal or distant metastatic involve-
ment, have an excellent prognosis after surgical resection
alone. However, those patients with metastatic disease at the
time of presentation are considered incurable and are treated
with palliative intent.1–4
Intermediate in prognosis between these two extremes
are the patients with locally advanced (T2-4) or regional (N1,
M1a) disease. Despite having technically resectable tumors,
their prognosis is guarded after single modality surgery alone.
Patients with T3 N0 disease, for example, have a 5-year
survival below 30%, whereas those with nodal involvement,
irrespective of the extent of their primary tumor, have an
expected 5-year survival below 15%.2,4,5 These are patients
for whom the use of multimodality surgical adjuvant treat-
ment seems most attractive.
Over the last two decades, such multimodality combi-
nations of treatments have been extensively tested. Random-
ized phase III trials have explored induction chemotherapy
followed by surgical resection,6–9 induction concurrent che-
moradiotherapy followed by surgical resection,10–13 definitive
concurrent chemoradiotherapy alone without surgery,14–17 and
adjuvant postoperative chemotherapy18 or concurrent chemora-
diotherapy.19 Despite intensive investigation, the results have
been mixed, and a true consensus defining the optimal ap-
proach has not emerged. Evidence has been generated sup-
porting each of these treatment schedules, and the choice of
a multimodality approach often reflects institutional prefer-
ence or expertise, coupled with the specifics of individual
patient staging and characteristics.
Complicating these treatment choices has been the
recognized limitations of clinical staging. Endoscopic ultra-
sound, computerized tomography (CT), and positron emis-
sion tomography (PET) have been frequently performed in an
attempt to accurately assign a clinical stage and define the
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optimal treatment. Even when maximally used, the clinical stage
is inaccurate in 20% or more of patients.2,4,20 Indeed, most
clinical trials testing multimodality approaches have failed to
uniformly employ even these limited clinical staging tools.
At the Cleveland Clinic, our approach has included
comprehensive pretreatment clinical staging in an effort to
optimally define the overall treatment approach. Those pa-
tients with T1-2 N0 M0 disease proceed to surgical resection.
Patients with T3-4, N1, or M1a tumors have, in general, been
treated on one of a series of investigational protocols testing
induction concurrent chemoradiotherapy followed by surgical
resection.21–24 Patients with M1b tumors are treated with
palliative intent. Despite this algorithm, there remain patients
with locoregionally advanced disease who first undergo sur-
gical resection without induction therapy.25 Many are clini-
cally staged T1-2 N0 patients with unsuspected T3-4, N1, or
M1a disease found at surgery. Other patients present with
more advanced, but still technically resectable cancers and a
strong preference for initial resection, or a compelling indi-
cation for early surgical intervention such as continued bleed-
ing or perforation. The optimal treatment approach for such a
patient after surgery is ill defined. Although similar patients
with gastric (and gastroesophageal junction [GEJ]) cancers
have a demonstrated benefit after postoperative chemoradio-
therapy,19 only limited data have been generated for the
esophageal cancer patient.26–28
In an effort to address this relatively infrequent sce-
nario, in 1995 we began a prospective phase II trial of
postoperative concurrent chemoradiotherapy for patients with
T3-4, N1, or M1a disease after surgery. We reported on 31
patients in 2003.29 This report updates these initial results and
adds data from 19 additional patients.
PATIENTS AND METHODS
Patients were eligible for this trial if, after undergoing
primary surgical resection with curative intent for an esoph-
ageal or GEJ adenocarcinoma or squamous cell carcinoma,
pathologic staging revealed T3-4, N1, or M1a disease. Eligi-
ble surgical procedures included either a transthoracic or
transhiatal esophagogastrectomy or a total gastrectomy with
Roux-en-Y esophagojejunostomy. An R0 or R1 resection was
required. An extensive lymphadenectomy was routinely per-
formed in all patients except in those undergoing transhiatal
surgery. Surgery was performed at the Cleveland Clinic in all
but two cases.
All patients required an Eastern Cooperative Oncology
Group performance status of 0–1 and could not be entered on
this study if they had received any previous systemic chemo-
therapy or radiation therapy for any other malignancy. Pre-
existing liver, kidney, or hematologic dysfunction also ex-
cluded patients from study entry.
Either before surgical resection or before entry on trial
(or both), all patients underwent a full staging evaluation to
exclude the possibility of distant metastases. A full medical
history, physical examination, complete blood count, and
serum chemistries including blood urea nitrogen, creatinine,
calcium, phosphorus, alkaline phosphatase, aspartate amino-
transferase, lactic dehydrogenase, albumin, total protein, bil-
irubin, and uric acid were performed before initiation of
chemoradiotherapy. Fluorodeoxyglucose PET scanning was
not obtained routinely before 2001 when it became readily
available at our institution. However, all patients underwent
presurgical CT, and esophagogastroduodenoscopy, with en-
doscopic ultrasound (in the 48 patients undergoing surgery at
the Cleveland Clinic) to define their clinical stage. Staging
definitions were based on the American Joint Committee on
Cancer staging manual being used at the time of original
diagnosis.30 For esophagus cancer, these definitions have
changed little over this time period (editions 4–6).
The study was approved and reviewed yearly by the
Cleveland Clinic Foundation Institutional Review Board and
written informed consent was obtained from all patients before
beginning the treatment.
Between 6 and 10 weeks after surgery, concurrent
chemoradiotherapy was begun. Figure 1 details the treatment
schema. Radiotherapy (1.8 Gy/d to a dose of 50.4–59.4 Gy)
was administered concurrent with two cycles of 5-fluoroura-
cil (1000 mg/m2/d) and cisplatin (20 mg/m2/d) both given as
4-day continuous intravenous infusions during the first and
fourth weeks of the radiation therapy. Chemotherapy admin-
istration required hospitalization for appropriate hydration
and antiemetic therapy. Peripheral venous access was used
for the 5-fluorouracil administration.
Radiation therapy was delivered on linear accelerators
using6-MV photon beams. Either a two-dimensional (2DP) or
a three-dimensional treatment (3DP) planning approach was
used for delivery of therapy based on the preference of the
treating radiation oncologist. Radiation treatment planning was
performed using Plato Sunrise 2.6.3 (Nucletron, Veenendaal,
The Netherlands) or Pinnacle versions 6.2–7.6 (Phillips, Am-
sterdam, The Netherlands). 2DP and 3DP field borders were
based on pretreatment investigations and imaging, correlated
with the patient’s postoperative anatomy. In 2D, bony land-
marks helped define tumor and nodal regions at risk and
fluoroscopy localized the anastomosis. Fixed 5 cm craniocau-
dal, and 2 to 2.5 cm radial, margins were then set to map out
tumor limits to set the field borders. 2DP dosimetry was
generated at the central axis of the fields, the center of the
field, and at planes 1.0 to 1.5 cm inside the superior and
inferior margins of the treatment volume to ensure dose
uniformity. 3DP involved target volume delineation using
soft tissue anatomy as defined by axial CT slices. Presurgical
images (CT, PET) were fused to planning CT simulation
images. Involved esophagus and lymph nodes with American
Joint Committee on Cancer-defined regional nodes at risk
were included in the postoperative clinical target volume.
Wk          1        2  3        4        5        6
5-FU
Cisplatin
RT
5-FU:  1000mg/m²/d IV C.I. x 4 days
Cisplatin: 20mg/m²/d     IV C.I. x 4 days
RT:    50.4 – 59.4 Gy  @ 180 cGy daily
FIGURE 1. Treatment schema.
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Normal structures were contoured for each case. 3DP dose
was designed to provide coverage of the target accounting for
daily variations (planning target volume), and prescriptions
were never to less than the 95% isodose line. Dose-volume
histograms were used to verify that radiation plans optimized
target coverage and normal tissue sparing. Dose-volume
histograms were de facto not obtainable with 2DP. Represen-
tative treatment fields used in a patient with M1a disease and
close surgical margins are portrayed in Figures 2A, B.
Patients were seen at least weekly during their postop-
erative chemoradiotherapy to monitor and treat side effects,
particularly esophagitis and myelosupression. Hospitalization
with antibiotic therapy was required for neutropenia if asso-
ciated with fever. Hospitalization was also required if mu-
cositis or dysphagia precluded an adequate oral intake; how-
ever, most patients had a feeding jejunostomy tube placed at
the time of their surgery and could be alimented adequately
without the need for intravenous support or hospitalization.
After the completion of all treatment, patients were
evaluated every 3 months for evidence of disease recurrence.
Radiographic and endoscopic procedures were repeated as
clinically indicated. Disease progression was characterized as
either locoregional or metastatic, and sites of recurrence were
recorded.
Statistical Considerations
The primary end point for this trial was overall sur-
vival. Additional outcomes were defined for this analysis
including locoregional control, distant metastatic control, and
freedom from recurrence. The event corresponding to locore-
gional control is any local or regional failure. The event
corresponding to distant metastatic control is any distant
failure. The events corresponding to freedom from recurrence
are local, regional, or distant failure, and the event corre-
sponding to overall survival is all-cause mortality. All out-
comes were calculated from the date of surgery. When this
study was designed, the historical median survival after
surgery was approximately 12 months. With a 5% level of
significance, 46 patients would be required to have 90%
power to detect an improvement in this median survival to 24
months.31 Allowing for a 10% ineligibility/unevaluability
rate, the targeted accrual would increase to 50 patients.
Outcomes were estimated using the Kaplan-Meier method
and compared using the log-rank test. Analyses were done
using SAS software (SAS Institute, Inc., Cary, NC).
RESULTS
Between February 1995 and January 2006, all eligible
patients seen at the Cleveland Clinic were offered participa-
tion in this trial. Fifty such patients were identified and
enrolled. The patient and tumor characteristics are detailed in
Table 1. The median age was 59 (range, 33–76) years. A total
of 43 patients (86%) had a pathologic diagnosis of adenocar-
cinoma and 19 of the adenocarcinoma patients (44%) had
histologic evidence of Barrett esophagus. A transthoracic
FIGURE 2. Representative treatment fields for delivery of
postoperative radiotherapy in a patient with M1a distal
esophageal cancer and close surgical margins. A, Anterior
field (from a three-field technique) with blocks. B, Boost field
to anastomosis.
TABLE 1. Patient and Tumor Characteristics
Number (%)
Gender
Male 43 (86)
Female 7 (14)
Race
White 48 (96)
African American 2 (4)
Tumor location
Mid esophagus 4 (8)
Lower esophagus 10 (20)
Gastroesophageal junction 36 (72)
Histopathology
Adenocarcinoma 43 (86)
Squamous cell carcinoma 7 (14)
Tumor differentiation
Well differentiated 1 (2)
Moderately well differentiated 16 (32)
Poorly differentiated 33 (66)
Pathologic stage
T3 N0 7 (14)
T1 N1 6 (12)
T2 N1 2 (4)
T3 N1 31 (62)
T4 N1 1 (2)
T3 N1 M1a 3 (6)
Surgical procedures
Transhiatal esophagogastrectomy 5 (10)
Transthoracic esophagogastrectomy 37 (74)
Total gastrectomy 8 (16)
Surgical margins
Positive 9 (18)
Negative 41 (82)
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esophagogastrectomy had been performed in 37 patients
(74%), transhiatal esophagogastrectomy in five patients
(10%), and a total gastrectomy in eight patients (16%).
Pathologic staging is detailed and proved greater than the
clinical staging in 28 patients (56%). The median number of
nodes sampled at surgery was 18 (range, 4–50). The 43 N1
patients had a median of 3 (range, 1–18) positive nodes
identified. Nine patients (18%) had an R1 resection with
positive surgical margins. The likelihood of a positive surgi-
cal margin was not increased in those patients undergoing
total gastrectomy.
Toxicity from the postoperative concurrent chemora-
diotherapy, graded using Common Toxicity Criteria, is de-
tailed in Table 2. Of note are modest nausea, vomiting,
mucositis, and dysphagia. Renal dysfunction, with a transient
rise in serum creatinine to 1.8 mg/dl, was noted in only one
patient. Although 16 patients (32%) experienced grade 3–4
neutropenia (1000/mm3), hospitalization for neutropenia
with fever was required in only 4 patients (8%). Thirteen
other patients required an unplanned hospitalization for a
variety of different reasons. (Table 3) There were no toxic
deaths. The median administered radiation therapy dose was
50.4 (range, 10.8–60) Gy. All but three patients completed
all of their planned chemotherapy and radiation. Treatment
was halted after the first course of chemotherapy and only
limited radiation in one patient because of the development
of (presumably unrelated) ischemic colitis and in another
after an acute myocardial infarction that was not tempo-
rally related to the fluorouracil infusion. The third patient
completed chemotherapy but discontinued radiation after
40 Gy due to nausea.
With a median follow-up of 47 (range, 36–124)
months, the Kaplan-Meier 4-year projected overall survival is
51% (Figure 3), 4-year freedom from recurrence 50%, distant
metastatic control 56%, and locoregional control 86%. The
median survival is 53 months. These results seem better than
the 4-year projected survival of 44%, with a median survival
of 28 months as we first reported in 2003.29 An updated
analysis of the 31 patients included in this 2003 report has not
changed. However, the 19 additional patients added to our
series have, as a group experienced considerably improved
outcomes, with a projected 4-year survival of 58.5%, thus
improving the overall results. Although these 19 patients are
statistically similar in their pathologic stage, their clinical
staging was statistically earlier than the original 31 patients
first reported (p  0.007).
Pathologic stage, nonetheless, proved the most impor-
tant predictor for outcome. When comparing patients with
pathologic stage T3 N0, N1 M0, and M1a disease, the overall
survival (p 0.015, Figure 4), freedom from recurrence (p
0.034), and distant metastatic control (p  0.05) were better
in patients with earlier pathologic stage. It is of note that the
pathologic stage did not impact the probability of locore-
gional control, which was excellent in all patient subgroups.
FIGURE 3. Overall survival (n  50 patients).
FIGURE 4. Overall survival by pathologic stage.
TABLE 2. Chemoradiotherapy Toxicity (n  50)
Number (%)
Nausea, vomiting (grade 3) 4 (8)
Mucositis, dysphagia (grade 3) 6 (12)
Neutropenia (1000/mm3) 16 (32)
Neutropenia with hospitalization for fever 4 (8)
Thrombocytopenia (20,000/mm3) 2 (4)
Toxic death 0
TABLE 3. Unplanned Hospitalization (n  50)
Number (%)
Neutropenic fever 4 (8)
Nonneutropenic fever/infection 2 (4)
Nausea/anorexia/dehydration 3 (6)
Diarrhea 2 (4)
Venous thromboembolism 2 (4)
Ischemic colitis 1 (2)
Cholecystitis 1 (2)
Myocardial infarction 1 (2)
Cardiac dysrhythmia 1 (2)
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Tumor differentiation, margin positivity, and tumor
location (in patients with adenocarcinoma) did not impact
outcome. Although univariate analysis suggested that patients
with squamous cell carcinoma had a better freedom from
recurrence (p 0.05) and distant metastatic control rate (p
0.07) than those with adenocarcinoma, in a multivariable
model only stage proved predictive of outcome.
DISCUSSION
This is mature data from a prospective phase II trial
exploring the role of concurrent chemoradiotherapy in poor
prognosis esophageal and GEJ cancer patients after primary
surgical resection. Treatment toxicity was acceptable and the
median overall survival was 53 months with a projected 4-year
overall survival of 51%. These figures are promising, particu-
larly when compared with the historical results after surgery
alone1,2,4–7,29 or even to the data generated from trials exploring
preoperative induction chemoradiotherapy.10–13,21–24 A recent
series from the Cleveland Clinic, for example, reports a
3-year projected overall survival of only 28% with a freedom
from recurrence of 31% for patients with similar (although
clinically) staged T3, N1, or M1a disease.23 It is important to
stress, however, that these are not comparable patient popu-
lations. Most of the patients entered on the current study were
clinically felt to have earlier tumors, defining a patient cohort
with less advanced disease and therefore a better prognosis.
Despite its inherent inaccuracy, the importance of clinical stag-
ing is underscored by our observation of an improved outcome
in the 19 patients we added to our original cohort of 31 patients
reported in 2003.29 The improved outcome we observed can
likely be attributed to an earlier clinical stage in the more recent
patients, despite similarity in their pathologic stage.
Additionally, only those patients who had tolerated and
recovered from surgical resection were eligible for this trial.
Patients with significant perioperative morbidity impact the
results of induction chemoradiotherapy trials but were not
entered on this study. Thus, direct comparison of the results
from this postoperative experience with the reported results
after induction chemoradiation therapy is not appropriate.
There is very little high-level evidence to support a
postoperative concurrent chemoradiotherapeutic approach in
esophageal cancer.26,27 The only large phase III randomized
study was an Intergroup trial reported by Macdonald et al.19
for patients with gastric cancer. Although “approximately
20%” of these patients had a gastroesophageal malignancy,
the outcome of the GEJ patients was not specifically detailed.
Extrapolation of these results to patients with distal or
midesophageal primary tumors, or to those with squamous
cell carcinoma, is somewhat speculative but is a common
clinical practice. Similarly, data supporting a role for post-
operative single modality radiation or chemotherapy, al-
though of interest, is limited.18,28,32
Nonetheless, adjuvant concurrent chemoradiotherapy is
an attractive approach for several reasons. First, treatment in
a postoperative setting allows a treatment decision to be
based on the true pathologic stage rather than on the relatively
inaccurate clinical stage, thus avoiding the use of chemora-
diotherapy in those patients who might otherwise not require
this intervention.25 Similarly, a more accurate assessment of
disease extent for the radiotherapist is possible after surgical
resection and delineation of disease involvement. Second, the
use of chemoradiotherapy postoperatively addresses the on-
going concern about the increase in perioperative morbidity
and mortality seen after preoperative induction. Although
recent multimodality series have suggested an improvement
in this perioperative morbidity with careful attention to radio-
therapeutic, anesthetic, and surgical technique,23 any added
complications from preoperative chemoradiotherapy can be
avoided altogether with a postoperative treatment approach.
Third, preoperative dysphagia and issues of nutritional support
often compromise a patient’s tolerance of induction chemora-
diotherapy. In postoperative patients, dysphagia has been re-
lieved and postoperative alimentation can be supported by a
surgically placed feeding tube, thus allowing for better tolerance
of the intervention.
Potential disadvantages exist as well. Recovery after
esophagogastric resection is difficult and may preclude the
use of postoperative chemoradiotherapy in a significant num-
ber of patients. Despite better nutritional support, overall
functional status is often reduced after surgery, potentially
interfering with overall treatment tolerance. Furthermore, the
impact of the altered postoperative blood supply on the
delivery of chemotherapy and oxygenation of the tumor bed
must be considered, at least in theory, potentially detrimental,
and the difficulties of treatment planning after surgical resec-
tion and reconstruction cannot be underestimated.
Perhaps the greatest concern is that the use of a post-
operative adjuvant chemoradiotherapeutic approach elimi-
nates the potential benefit of induction treatment on the
success of surgery. This benefit, however, remains ill defined,
and it is unclear whether induction chemoradiotherapy actu-
ally improves resectability or the ultimate outcome after
treatment.
CONCLUSION
Although the use of multiple treatment modalities in
patients with locoregionally advanced esophageal cancer
seems better than single modality surgery alone, the optimal
order in which these treatments should be used is unknown.
Meta-analysis data suggests a significant benefit from induc-
tion chemoradiotherapy before surgical resection, and this
has become a standard of care.33 We suggest that postoper-
ative concurrent chemoradiotherapy can be successful and
may have significant advantages for the clinically under-
staged patient or for the patient with locoregionally more
advanced but resectable disease who undergoes initial surgi-
cal resection for another reason. Further study of this ap-
proach, particularly in comparison with preoperative chemo-
radiotherapy, is justified.
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